Normand Blais

USPTO Granted Patents = 21 (Patent Applications = 6)

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 13 (Patent Applications = 20)

Average Co-Inventor Count = 3.9

ph-index = 5

Forward Citations = 112(Granted Patents)

Location History:

Lava, CA (2013)
Laval, CA (2012 - 2021)

Company Filing History:

20 out of 531

Glaxosmithkline Biologicals Sa

where one patent can have more than one assignee

Years Active: 2012-2021

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11198707 - Fusion proteins and combination vaccines comprisingProtein E and Pilin A (2021-12-14),

2. 10947280 - UspA2 protein constructs and uses thereof (2021-03-16),

3. 10745449 - UspA2 protein constructs and uses thereof (2020-08-18),

4. 10730917 - Fusion proteins and combination vaccines comprising haemophilus influenzae Protein E and Pilin A (2020-08-04),

5. 10214569 - [object Object] (2019-02-26),

6. 10040832 - UspA2 protein constructs and uses thereof (2018-08-07),

7. 10023616 - [object Object] (2018-07-17),

8. 9994622 - Expression system (2018-06-12),

9. 9492531 - Recombinant RSV vaccines (2016-11-15),

10. 9422345 - Expression system (2016-08-23),

11. 9409957 - [object Object] (2016-08-09),

12. 9296794 - [object Object] (2016-03-29),

13. 9200044 - Modified antigens (2015-12-01),

14. 9161975 - Immunogenic composition (2015-10-20),

15. 8987423 - MAGE antigen binding proteins (2015-03-24),

Title: Normand Blais: Leading the Way in Innovation

Introduction:

Normand Blais, a visionary inventor hailing from Laval, Canada, is spearheading a revolution in the realms of healthcare and biotechnology. With 21 patents to his name and a relentless drive for progress, Blais is making waves in the industry with his groundbreaking innovations.

Latest Patents:

Blais's latest patents include the development of Fusion Proteins and Combination Vaccines comprising Protein E and Pilin A. These patents focus on treating chronic hepatitis B infection in humans by leveraging innovative methods and composition comprising UspA2 protein constructs.

Career Highlights:

Having worked with reputable companies like GlaxoSmithKline Biologicals SA and Glaxo Group Limited, Blais has honed his skills and expertise in the field of biotechnology. His contributions have not only advanced scientific research but have also paved the way for novel treatment modalities in chronic diseases.

Collaborations:

Throughout his career, Blais has collaborated with esteemed professionals in the field, including his coworkers Steve Labbe and Jan Poolman. Their joint efforts have resulted in pioneering research and the development of cutting-edge technologies that have the potential to revolutionize the healthcare industry.

Conclusion:

Normand Blais stands as a beacon of innovation, pushing the boundaries of what is possible in the field of biotechnology. His passion for creating a better future through inventive solutions continues to leave a lasting impact on the world, shaping the landscape of healthcare and inspiring future generations of inventors.

This text is generated by artificial intelligence and may not be accurate.